Fourth German Hospital Selects IntraOp Medical Corporation’s Mobetron

SUNNYVALE, Calif.--(BUSINESS WIRE)-- IntraOp Medical Corporation (OTC: IOPD.PK - News) today announced that Helios Berlin Buch became the fourth German hospital and the nineteenth European hospital to purchase a Mobetron for Intra-Operative Electron Radiation Therapy (IOERT).

“IOERT is becoming the gold standard in the successful treatment of cancer,” says Ernesto G. Lanzotti, Director of MD51 Germany GmbH, IntraOp Medical European distributor. “The clinical data showing the effectiveness of IOERT, compared to conventional treatment is very convincing. German hospitals are all looking to provide their patients the best cancer treatment possible—and that is IOERT. We are very proud to start cooperating with helios-kliniken.de because we understand the importance from both a treatment and medical science aspect and the potential they will be able to bring in terms of future treatments. With our existing German customers already operating in Germany at a level of excellence, we are sure IOERT will have a big increase already in the next few months.”

Helios Berlin Buch in the city of Berlin is the reference site among most important treatment centers in Germany, very famous for its Breast Cancer unit and for the state of the art in Medical Technology.

“We are very excited to add Helios Group to a growing list of world class cancer centers using the Mobetron. IOERT for breast cancer is becoming very prevalent throughout Europe,” said John Powers, President and CEO of IntraOp Medical. IntraOp’s Mobetron is a mobile, self-shielded, device that delivers radiation directly to the tumor site during cancer surgery protecting surrounding body structures from radiation. This procedure is called IORT. The Mobetron uses electron radiation, IOERT, which is the fastest, safest, most versatile, and precise way to deliver radiation therapy. The Mobetron delivers concentrated electron radiation directly to the exposed tumor bed to an exact depth during cancer surgery.

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer IOERT safely and effectively for all cancer patients. The Mobetron is the first IOERT device designed for use in existing operating rooms or office settings and has been used to treat over 20 different cancer indications. Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals and clinics in North America, Europe, and Asia, use the Mobetron as a vital part of their comprehensive cancer program.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.



CONTACT:

IntraOp Medical Corporation
John Powers, 847-404-0644

KEYWORDS:   United States  Europe  North America  California  Germany

INDUSTRY KEYWORDS:   Surgery  Health  Biotechnology  Fitness & Nutrition  Hospitals  Medical Devices  Other Health  Professional Services  Insurance  Nursing  General Health  Managed Care

MEDIA:

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.